JP2013510123A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510123A5
JP2013510123A5 JP2012537381A JP2012537381A JP2013510123A5 JP 2013510123 A5 JP2013510123 A5 JP 2013510123A5 JP 2012537381 A JP2012537381 A JP 2012537381A JP 2012537381 A JP2012537381 A JP 2012537381A JP 2013510123 A5 JP2013510123 A5 JP 2013510123A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
salt
membered
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012537381A
Other languages
English (en)
Japanese (ja)
Other versions
JP5702396B2 (ja
JP2013510123A (ja
Filing date
Publication date
Priority claimed from GB0919433A external-priority patent/GB0919433D0/en
Priority claimed from GBGB1010509.6A external-priority patent/GB201010509D0/en
Priority claimed from PCT/EP2010/061518 external-priority patent/WO2011054553A1/en
Priority claimed from GBGB1014231.3A external-priority patent/GB201014231D0/en
Application filed filed Critical
Priority claimed from PCT/EP2010/066697 external-priority patent/WO2011054845A1/en
Publication of JP2013510123A publication Critical patent/JP2013510123A/ja
Publication of JP2013510123A5 publication Critical patent/JP2013510123A5/ja
Application granted granted Critical
Publication of JP5702396B2 publication Critical patent/JP5702396B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012537381A 2009-11-05 2010-11-03 ベンゾジアゼピンブロモドメイン阻害剤 Expired - Fee Related JP5702396B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0919433.3 2009-11-05
GB0919433A GB0919433D0 (en) 2009-11-05 2009-11-05 Novel compounds
GB1010509.6 2010-06-22
GBGB1010509.6A GB201010509D0 (en) 2010-06-22 2010-06-22 Novel compounds
EPPCT/EP2010/061518 2010-08-06
PCT/EP2010/061518 WO2011054553A1 (en) 2009-11-05 2010-08-06 Benzodiazepine bromodomain inhibitor
GB1014231.3 2010-08-25
GBGB1014231.3A GB201014231D0 (en) 2010-08-25 2010-08-25 Novel compounds
PCT/EP2010/066697 WO2011054845A1 (en) 2009-11-05 2010-11-03 Benzodiazepine bromodomain inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015030132A Division JP2015143232A (ja) 2009-11-05 2015-02-19 ベンゾジアゼピンブロモドメイン阻害剤

Publications (3)

Publication Number Publication Date
JP2013510123A JP2013510123A (ja) 2013-03-21
JP2013510123A5 true JP2013510123A5 (enExample) 2013-11-21
JP5702396B2 JP5702396B2 (ja) 2015-04-15

Family

ID=43969589

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012537381A Expired - Fee Related JP5702396B2 (ja) 2009-11-05 2010-11-03 ベンゾジアゼピンブロモドメイン阻害剤
JP2015030132A Pending JP2015143232A (ja) 2009-11-05 2015-02-19 ベンゾジアゼピンブロモドメイン阻害剤
JP2016185487A Pending JP2017039738A (ja) 2009-11-05 2016-09-23 ベンゾジアゼピンブロモドメイン阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015030132A Pending JP2015143232A (ja) 2009-11-05 2015-02-19 ベンゾジアゼピンブロモドメイン阻害剤
JP2016185487A Pending JP2017039738A (ja) 2009-11-05 2016-09-23 ベンゾジアゼピンブロモドメイン阻害剤

Country Status (23)

Country Link
US (3) US9102677B2 (enExample)
EP (2) EP3050885B1 (enExample)
JP (3) JP5702396B2 (enExample)
KR (1) KR20120097508A (enExample)
CN (1) CN102781943B (enExample)
AU (1) AU2010317096B2 (enExample)
BR (1) BR112012010705A2 (enExample)
CA (1) CA2779423C (enExample)
CY (1) CY1117424T1 (enExample)
DK (1) DK2496582T3 (enExample)
EA (1) EA023441B1 (enExample)
ES (2) ES2564318T3 (enExample)
HK (1) HK1221221A1 (enExample)
HR (1) HRP20160253T1 (enExample)
HU (1) HUE026967T2 (enExample)
IL (2) IL219253A (enExample)
ME (1) ME02356B (enExample)
MX (1) MX341212B (enExample)
PL (1) PL2496582T3 (enExample)
RS (1) RS54645B1 (enExample)
SI (1) SI2496582T1 (enExample)
SM (1) SMT201600104B (enExample)
WO (1) WO2011054845A1 (enExample)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170091770A (ko) 2006-07-10 2017-08-09 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
BR112012010705A2 (pt) * 2009-11-05 2016-03-29 Glaxosmithkline Llc composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
EP2571875A4 (en) 2010-05-14 2013-10-30 Dana Farber Cancer Inst Inc CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF
PL2571503T3 (pl) 2010-05-14 2015-06-30 Dana Farber Cancer Inst Inc Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033268A2 (en) * 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
DE102011082013A1 (de) * 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP2838881B1 (en) 2012-04-20 2018-08-08 AbbVie Inc. Isoindolone derivatives
SI2852389T1 (en) * 2012-05-22 2018-02-28 Paion Uk Limited Compositions comprising short-acting benzodiazepines
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
WO2013185284A1 (en) 2012-06-12 2013-12-19 Abbott Laboratories Pyridinone and pyridazinone derivatives
KR20150042231A (ko) 2012-08-16 2015-04-20 글락소스미스클라인 엘엘씨 소세포폐암을 치료하기 위한 벤조디아제핀
EA201590356A1 (ru) 2012-08-16 2015-07-30 Байер Фарма Акциенгезельшафт 2,3-бензодиазепины
ES2625959T3 (es) * 2012-09-28 2017-07-21 Bayer Pharma Aktiengesellschaft 5-Aril-triazolo-azepinas inhibidoras de la proteína BET
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2014164780A1 (en) * 2013-03-11 2014-10-09 Abbvie Inc. Fused tetracyclic bromodomain inhibitors
JP6401773B2 (ja) 2013-03-11 2018-10-10 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Betブロモドメイン阻害剤およびこれを用いる治療方法
EP2970330B1 (en) * 2013-03-12 2019-04-17 AbbVie Inc. Tetracyclic bromodomain inhibitors
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
WO2014159837A1 (en) 2013-03-14 2014-10-02 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
CA2903881C (en) 2013-03-15 2021-05-18 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
EA027139B1 (ru) 2013-04-26 2017-06-30 Бейджин, Лтд. Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
CN103202815B (zh) * 2013-05-05 2014-09-24 李友香 治疗精神疾病的注射剂
CN104146970A (zh) * 2013-05-05 2014-11-19 王元青 治疗精神疾病的冻干粉针剂
CA2915622C (en) 2013-06-21 2020-08-18 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
SG11201510409QA (en) 2013-06-21 2016-01-28 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors
US9290514B2 (en) 2013-07-08 2016-03-22 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
WO2015013635A2 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
US9855271B2 (en) 2013-07-31 2018-01-02 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
GB201320994D0 (en) * 2013-11-28 2014-01-15 Univ Dundee Enzyme function probes
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
MX2016009976A (es) 2014-01-31 2016-11-15 Dana Farber Cancer Inst Inc Derivados de diazepam y sus usos.
EP3105232B1 (en) 2014-02-10 2019-08-28 Concert Pharmaceuticals Inc. Substituted triazolobenzodiazepines
CN106456653A (zh) 2014-02-28 2017-02-22 腾沙治疗公司 高胰岛素血症相关病症的治疗
CA2940554A1 (en) 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
EP3129378B1 (en) * 2014-04-09 2019-06-26 Kainos Medicine, Inc. Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer
DK3674302T3 (da) 2014-04-23 2023-04-03 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner
CA2952526A1 (en) * 2014-06-18 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-protein inhibiting 3,4-dihydropyrido[2,3-b]pyrazinones with meta-substituted aromatic amino- or ether groups
ES2725928T3 (es) 2014-06-20 2019-09-30 Constellation Pharmaceuticals Inc Formas cristalinas de 2-((4S)-6-(4-clorofenil)-1-metil-4H-benzo[c]isoxazolo[4,5-e]azepin-4-il)acetamida
CA2955077A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
WO2016022902A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
EP3194406B8 (en) 2014-09-15 2021-03-31 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
EP3201199A1 (en) * 2014-10-02 2017-08-09 Glaxosmithkline Intellectual Property (No. 2) Limited Compound
MX376748B (es) 2014-10-27 2025-03-07 Tensha Therapeutics Inc Inhibidores del bromodominio.
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
HK1245248B (en) 2014-12-11 2020-05-15 恒翼生物医药(上海)股份有限公司 Substituted heterocycles as bromodomain inhibitors
HK1245247A1 (zh) 2014-12-17 2018-08-24 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
EP3262045A1 (en) 2015-02-27 2018-01-03 The Regents of The University of Michigan 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
SMT202100593T1 (it) 2015-03-31 2021-11-12 Enanta Pharm Inc Derivati degli acidi biliari come agonisti di fxr/tgr5 e metodi per il loro uso
WO2016171470A1 (en) * 2015-04-21 2016-10-27 Kainos Medicine, Inc. Bromodomain-inhibiting compounds and methods to prevent or treat a cancer
WO2016196065A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Methods and compositions for assessing responsiveness of cancers to bet inhibitors
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
JP2018520124A (ja) 2015-06-26 2018-07-26 テンシャ セラピューティクス,インコーポレイテッド Nut正中線癌の治療
JP6765622B2 (ja) * 2015-07-17 2020-10-07 日本光電工業株式会社 救命支援装置
PT3324977T (pt) 2015-07-22 2022-10-14 Enanta Pharm Inc Derivados de benzodiazepina como inibidores de vsr
JP2018526424A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
KR20180049058A (ko) 2015-09-11 2018-05-10 다나-파버 캔서 인스티튜트 인크. 시아노 티에노트리아졸로디아제핀 및 그의 용도
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
CN114957291A (zh) 2015-11-25 2022-08-30 达纳-法伯癌症研究所股份有限公司 二价溴结构域抑制剂及其用途
CN106892924B (zh) * 2015-12-17 2021-01-08 四川科伦博泰生物医药股份有限公司 短效苯并二氮*衍生物、其制备方法及其用途
US20170226129A1 (en) 2016-01-15 2017-08-10 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
AU2017219627B2 (en) 2016-02-15 2021-08-05 The Regents Of The University Of Michigan Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
AU2017246453A1 (en) 2016-04-06 2018-11-08 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
SG11201808729WA (en) 2016-04-12 2018-11-29 Univ Michigan Regents Bet protein degraders
BR112018071216A2 (pt) 2016-04-15 2019-02-05 Abbvie Inc inibidores de bromodomínios
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
CA3220957A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor
CN107629057B (zh) * 2016-07-19 2020-03-27 上海勋和医药科技有限公司 Bet蛋白抑制剂及其应用
EP3490552B1 (en) 2016-07-26 2022-11-23 University of Southern California Selective bromodomain inhibition of fungal bdf1
US11466028B2 (en) 2016-09-13 2022-10-11 The Regents Of The University Of Michigan Fused 1,4-oxazepines as BET protein degraders
CN110072866A (zh) 2016-09-13 2019-07-30 密执安大学评议会 作为bet蛋白降解剂的稠合的1,4-二氮杂*
BR112019006651A2 (pt) 2016-10-04 2019-07-02 Enanta Pharm Inc análogos de isoxazol como agonistas de fxr e métodos de uso do mesmo
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
US20190284192A1 (en) 2016-11-10 2019-09-19 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof
WO2018129287A1 (en) * 2017-01-06 2018-07-12 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as rsv inhibitors
EP3577120A1 (en) 2017-02-03 2019-12-11 The Regents of The University of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
JP7076459B2 (ja) 2017-02-16 2022-05-27 エナンタ ファーマシューティカルズ インコーポレイテッド ベンゾジアゼピン誘導体の製造プロセス
CN108727380A (zh) * 2017-04-13 2018-11-02 中国科学院上海药物研究所 一种brd4抑制剂及其制备和应用
CN110418791B (zh) * 2017-04-28 2022-07-01 四川科伦博泰生物医药股份有限公司 包含苯并二氮䓬类化合物的注射用组合物及其制备方法
CN108948018B (zh) * 2017-05-17 2021-03-30 四川科伦博泰生物医药股份有限公司 苯并二氮*衍生物及其盐和相关晶体形式、制备方法和用途
US10752598B2 (en) 2017-06-07 2020-08-25 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as RSV inhibitors
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019055444A1 (en) 2017-09-13 2019-03-21 The Regents Of The University Of Michigan DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS
US11312726B2 (en) * 2017-09-22 2022-04-26 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Thienodiazepine derivatives and application thereof
US10881666B2 (en) 2017-09-29 2021-01-05 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as RSV inhibitors
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
US10501422B2 (en) 2017-11-13 2019-12-10 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
TWI888359B (zh) * 2018-09-11 2025-07-01 瑞士商赫孚孟拉羅股份公司 噻吩并-三唑并-二氮呯醋酸酯
JP7292400B2 (ja) * 2019-03-07 2023-06-16 メッドシャイン ディスカバリー インコーポレイテッド BET Bromodomainタンパク質の阻害とPD-L1遺伝子の調節の両方の効果を持つ化合物
PH12021552201A1 (en) 2019-03-18 2022-05-30 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
US11572367B2 (en) 2019-10-04 2023-02-07 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
PT116050B (pt) * 2020-01-09 2022-06-15 Hovione Farm S A Conjugados fármaco-ligando e inibidores das proteínas da família bromodomínio e domínio extraterminal -(bet) modificados
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3185149A1 (en) 2020-06-23 2021-12-30 Genentech, Inc. Macrocyclic compounds and methods of use thereof
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
GB202016977D0 (en) 2020-10-26 2020-12-09 In4Derm Ltd Compounds
CN112358483A (zh) * 2020-11-09 2021-02-12 中国药科大学 一类新型苯并二氮*类化合物、其制备方法及其用途
CN114456171A (zh) * 2020-11-09 2022-05-10 中国药科大学 一类用于镇静催眠的苯并二氮䓬类药物、其制备方法及应用
US11945830B2 (en) 2021-02-26 2024-04-02 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
AU2022303310A1 (en) 2021-06-29 2024-02-08 Tay Therapeutics Limited Pyrrolopyridone derivatives useful in the treatment of cancer
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
EP4511119A1 (en) 2022-04-19 2025-02-26 Nuevolution A/S Compounds active towards bromodomains
US12162857B2 (en) 2022-04-27 2024-12-10 Enanta Pharmaceuticals, Inc. Antiviral compounds
EP4558224A1 (en) 2022-07-21 2025-05-28 Tay Therapeutics Limited Pyrroles and imidazoles as bet protein inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1152066A (en) 1980-02-08 1983-08-16 Hoffmann-La Roche Limited Benzodiazepine derivatives
DE3610848A1 (de) * 1986-04-01 1987-10-15 Boehringer Ingelheim Kg Neue 1,4-diazepine
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5593988A (en) 1991-10-11 1997-01-14 Yoshitomi Pharmaceutical Industries, Ltd. Therapeutic agent for osteoporosis and diazepine compound
JPH06128257A (ja) 1992-10-13 1994-05-10 Yoshitomi Pharmaceut Ind Ltd ピリドジアゼピン化合物
WO1995014694A1 (en) 1993-11-22 1995-06-01 Merck & Co., Inc. Benzodiazepines
US5807850A (en) 1994-11-18 1998-09-15 Japan Tobacco, Inc. Therapeutic agent for osteoporosis and triazepine compound
JP2622673B2 (ja) * 1994-11-18 1997-06-18 日本たばこ産業株式会社 骨粗鬆症治療薬およびトリアゼピン化合物
IL127516A0 (en) * 1996-06-12 1999-10-28 Japan Tobacco Inc A cytokine production inhibitor
AU716490B2 (en) 1996-09-13 2000-02-24 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compounds and pharmaceutical use thereof
JPH11228576A (ja) * 1997-12-10 1999-08-24 Japan Tobacco Inc アポトーシス抑制剤
US6916995B2 (en) 2003-02-25 2005-07-12 Broadcom Corporation Optimization of routing layers and board space requirements for ball grid array package implementations including single and multi-layer routing
PL1699512T3 (pl) 2003-11-03 2012-11-30 Glaxo Group Ltd Urządzenie do dozowania płynów
CN1739788A (zh) 2004-03-31 2006-03-01 新加坡国立大学 Trip-br功能的调节和治疗增殖性紊乱的方法
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
EP1887008B1 (en) 2005-05-30 2021-04-21 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compound and a medicinal use thereof
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Brd2ブロモドメイン結合剤
CA2710740C (en) * 2007-12-28 2016-07-19 Shinji Miyoshi Thienotriazolodiazepine compound as antitumor agent
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
BR112012010705A2 (pt) * 2009-11-05 2016-03-29 Glaxosmithkline Llc composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio
ME02360B (me) * 2009-11-05 2016-06-20 Glaxosmithkline Llc Inhibitor bromodomena benzodiazepina

Similar Documents

Publication Publication Date Title
JP2013510123A5 (enExample)
JP2013510124A5 (enExample)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2014511892A5 (enExample)
JP2015511638A5 (enExample)
JP2013510120A5 (enExample)
JP2019510832A5 (enExample)
RU2018105549A (ru) Производные бензодиазепина как ингибиторы rsv
EA200901155A1 (ru) Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
JP2014511891A5 (enExample)
RU2017104856A (ru) Функционализированные и замещенные индолы в качестве противораковых средств
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
JP2016523974A5 (enExample)
JP2016530283A5 (enExample)
RU2012112050A (ru) Производные дигидроптеридинона, способ их получения и фармацевтическое применение
JP2016518437A5 (enExample)
JP2012524055A5 (enExample)
JP2014505107A5 (enExample)
JP2013542261A5 (enExample)
JP2017523169A5 (enExample)
JP2014514349A5 (enExample)
JP2013507415A5 (enExample)
JP2014501766A5 (enExample)
JP2009507896A5 (enExample)
JP2015504091A5 (enExample)